This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
n5http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/wikipedia/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00406/identifier/drugbank/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00406
rdf:type
n3:Drug
n3:description
A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties. [PubChem]
n3:dosage
n24:271B456C-363D-11E5-9242-09173F13E4C5 n24:271B456D-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of Chagas' disease (as a blood additive).
n3:manufacturer
n14:271B4568-363D-11E5-9242-09173F13E4C5 n14:271B4569-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00406 n13:DB00406
dcterms:title
Gentian Violet
adms:identifier
n8:Gentian_Violet n17:3349 n18:DB00406 n19:46505353 n20:PA449755 n22:3468 n23:D01046
n3:mechanismOfAction
In aqueous solutions Gentian violet (GV) dissociates into positive (GV+)and negative ions (Cl-) that penetrate through the wall and membrane of both gram-positive and gram-negative bacterial cells. The GV+ interacts with negatively charged components of bacterial cells including the lipopolysaccharide (on the cell wall), the peptidoglycan and DNA. A similar cell penetration and DNA binding process is thought to take place for fungal cells as well. Because Gentian violet is a mutagen and mitotic poison, cell growth is consequently inhibited. A photodynamic action of gentian violet, apparently mediated by a free-radical mechanism, has recently been described in bacteria and in the protozoan T. cruzi. Evidence also suggests that gentian violet dissipates the bacterial (and mitochondrial) membrane potential by inducing permeability. This is followed by respiratory inhibition. This anti-mitochondrial activity might explain gentian violet's efficacy towards both bacteria and yeast with relatively mild effects on mammalian cells.
n3:packager
n14:271B4567-363D-11E5-9242-09173F13E4C5
n3:synonym
Crystal violet(1+) Gentian violet carbocation Gentian violet(1+) Crystal violet carbocation Crystal Violet Gentian violet cation Methyl Violet 10B Pyoctanin Pyoctanine Crystal violet ion(1)
n3:toxicity
LD<sub>50</sub>=420 mg/kg (rat, oral). Oral administration can cause gastrointestinal irritation, and intravenous injection can cause depression in the white blood cell count.
n11:hasAHFSCode
n12:84-04-08-92
n3:salt
n3:synthesisReference
Hiep Do, Daniel J. Spangler, Joel Rosenblatt, Barrett Remington, Onajite Okoh, "High concentration gentian violet containing medical devices and methods of making same." U.S. Patent US20090130171, issued May 21, 2009.
n15:hasConcept
n16:M0009174
foaf:page
n5:gentian-violet-topical.html
n3:IUPAC-Name
n6:271B4572-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4578-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4577-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4574-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4575-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4576-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4570-363D-11E5-9242-09173F13E4C5 n6:271B4587-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4571-363D-11E5-9242-09173F13E4C5 n6:271B4589-363D-11E5-9242-09173F13E4C5 n6:271B456E-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B456F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B457E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B457F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4579-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B457A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B457C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B457B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B457D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Yeast and other fungi Bacteria and protozoa
n3:casRegistryNumber
14426-25-6
n3:category
n3:containedIn
n21:271B456A-363D-11E5-9242-09173F13E4C5 n21:271B456B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4583-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4585-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4586-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B4588-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4582-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4581-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4584-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4573-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4580-363D-11E5-9242-09173F13E4C5